Arakis is a wholly owned subsidiary of Sosei whose remit is to provide benefit to patients and value to shareholders by discovering, developing and commercialising innovative medicinal products based on established drugs and drug templates. Its chosen therapeutic areas are inflammatory disease and pain. The risks of taking a New Chemical Entity from concept to market are high; it can take over 10 years and costs in excess of £300 million. Arakis' approach, based on identifying new indications or uses for established drugs or drug templates, reduces the risk in the following manner: the pharmacology and safety of the drug is already well understood it is possible to bridge to existing data early proof-of-principle in man can be established the API is available or can be manufactured quickly, so minimising process research and development expenditure. As a consequence of its business model, Arakis has efficiently developed (both in terms of time and cost) a late stage clinical pipeline. Arakis was founded in March 2000 and raised over £49 million in three private equity funding rounds. The company is based at Chesterford Research Park, south of Cambridge, UK and currently has 38 employees.
Fresenius AG is one of the leading health care companies worldwide with products and services for dialysis, the hospital and the outpatient medical care of patients. In 1998 Fresenius generated sales of DM 8.444 billion (US $4.593 billion) and a net income of DM 285 million (US $155 million). On December 31, 1998, the Fresenius Group had more than 39,000 employees.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory